trending Market Intelligence /marketintelligence/en/news-insights/trending/wushtof-gagt-swn4qdbmq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Innovus secures rights to allergy drug in US, Canada

South Korean Multichannel Industry To Survive With Right Strategies

South Korean Telcos Drive Next Wave Of Growth Through Home IoT Opportunities

Mining Exploration Insights: Financing Falls To 8-Month Low In October

Taking Advantage of Issuance Trends in 2020


Innovus secures rights to allergy drug in US, Canada

Innovus Pharmaceuticals Inc. secured a contract to market NTC Srl's Lertal tablets in U.S. and Canada under the AllerVarx brand name.

Innovus is making an undisclosed up-front payment to the Italian company and has agreed to make further milestone-related payments as a result of the agreement.

Lertal is used for the treatment of allergic rhinitis.